Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,956 questions in 143 reviews · Musculoskeletal

current versions

No studies 555 · 28.4%Ungraded 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
NSAID injection vs glucocorticoid injection Residual pain · adults (> 18 years of age) with trigger finger Non‐steroidal anti‐inflammatory drugs (NSAIDs) for trigger finger (2021) · Cochrane	RR 0.84 [0.54, 1.31]	2 studies · 231 participants	Low
NSAID injection vs glucocorticoid injection Participant‐reported treatment success · adults (> 18 years of age) with trigger finger Non‐steroidal anti‐inflammatory drugs (NSAIDs) for trigger finger (2021) · Cochrane	RR 0.95 [0.74, 1.23]	1 study · 121 participants	Low
NSAID injection vs glucocorticoid injection Adverse events · adults (> 18 years of age) with trigger finger Non‐steroidal anti‐inflammatory drugs (NSAIDs) for trigger finger (2021) · Cochrane	RR 2	2 studies · 231 participants	Very low
Mepolizumab vs placebo Mortality · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	Peto OR 7.39 [0.15, 372.38]	NR	Low
Active drug (etanercept or belimumab) with standard therapy vs standard therapy with placebo Remission (number of patients with remission) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of… Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 0.97 [0.89, 1.07]	NR	Low
Active drug (etanercept or belimumab) with standard therapy vs standard therapy with placebo Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of… Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 0.93 [0.77, 1.11]	NR	Low
Active drug (etanercept or belimumab) with standard therapy vs standard therapy with placebo Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of… Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 2.94 [0.12, 70.67]	NR	Low
Active drug (etanercept or belimumab) with standard therapy vs standard therapy with placebo Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of… Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 0.98 [0.76, 1.27]	NR	Moderate
Active drug (etanercept or belimumab) with standard therapy vs standard therapy with placebo Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of… Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 1.12 [0.97, 1.29]	NR	Low
Active drug (etanercept or belimumab) with standard therapy vs standard therapy with placebo Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of… Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 1 [0.8, 1.27]	NR	Low
Active drug (etanercept or belimumab) with standard therapy vs standard therapy with placebo Any withdrawals due to AE · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of… Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 2.66 [1.07, 6.59]	NR	Low
Infliximab vs rituximab Mortality · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	Peto OR 0.88 [0.05, 15.51]	NR	Very low
Infliximab vs rituximab Remission · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 0.44 [0.11, 1.81]	NR	Very low
Infliximab vs rituximab Durable remission during additional · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 0.22 [0.03, 1.6]	NR	Very low
Mepolizumab vs placebo Remission for at least 24 weeks · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 9.5 [2.3, 39.21]	NR	Low
Infliximab vs rituximab Disease flare/relapse · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs rituximab Any adverse event · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs rituximab Any severe AEs · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 1.78 [0.2, 16.1]	NR	Very low
Infliximab vs rituximab Any withdrawals due to AEs · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 2.7 [0.13, 58.24]	NR	Very low
Mepolizumab vs placebo Durable remission within the first 24 weeks sustained until week 52 · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 13 [1.75, 96.33]	NR	Low
Mepolizumab vs placebo Disease relapse · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 0.68 [0.53, 0.86]	NR	Moderate
Mepolizumab vs placebo Disease flares · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	no estimate extracted	NR	No studies
Mepolizumab vs placebo Any adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 1.03 [0.96, 1.11]	NR	Low
Mepolizumab vs placebo Any serious adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 0.67 [0.35, 1.28]	NR	Low
Mepolizumab vs placebo Any withdrawals due to AEs · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	RR 2 [0.19, 21.54]	NR	Low
Active drug (etanercept or belimumab) with standard therapy vs standard therapy with placebo MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of… Anti‐cytokine targeted therapies for ANCA‐associated vasculitis (2020) · Cochrane	Peto OR 2.45 [0.55, 10.97]	NR	Low
Shock wave therapy vs placebo Pain relief > 50%a · rotator cuff disease with or without calcification Shock wave therapy for rotator cuff disease with or without calcification (2020) · Cochrane	RR 1.1 [0.62, 1.94]	1 study · 74 participants	Low
Shock wave therapy vs placebo Pain Multiple scalese translated to VAS 0–10 (10 was severe pain)f · rotator cuff disease with or without calcification Shock wave therapy for rotator cuff disease with or without calcification (2020) · Cochrane	no estimate extracted	9 studies · 608 participants	Moderate
Shock wave therapy vs placebo Function Multiple scalese translated to Constant 0–100 scale (100 was best function)f · rotator cuff disease with or without calcification Shock wave therapy for rotator cuff disease with or without calcification (2020) · Cochrane	SMD 0.62 [0.13, 1.11]	9 studies · 612 participants	Moderate
Shock wave therapy vs placebo Participant‐reported success · rotator cuff disease with or without calcification Shock wave therapy for rotator cuff disease with or without calcification (2020) · Cochrane	RR 1.59 [0.87, 2.91]	6 studies · 287 participants	Low
Shock wave therapy vs placebo Quality of life · rotator cuff disease with or without calcification Shock wave therapy for rotator cuff disease with or without calcification (2020) · Cochrane	no estimate extracted	NR	No studies
Shock wave therapy vs placebo Number of participant withdrawals due to adverse events or treatment intolerance · rotator cuff disease with or without calcification Shock wave therapy for rotator cuff disease with or without calcification (2020) · Cochrane	RR 0.75 [0.43, 1.31]	7 studies · 581 participants	Low
Shock wave therapy vs placebo Number of participants experiencing any adverse event · rotator cuff disease with or without calcification Shock wave therapy for rotator cuff disease with or without calcification (2020) · Cochrane	RR 3.61 [2, 6.52]	5 studies · 295 participants	Low
Knee replacement with tourniquet vs knee replacement without tourniquet Pain Visual analogue scale (VAS) for pain from zero to 10 (higher scores indicate more pain) Tourniquet use for knee replacement surgery (2020) · Cochrane	no estimate extracted	8 studies · 577 participants	Moderate
Knee replacement with tourniquet vs knee replacement without tourniquet Function Similar 0 to 100 scales (100 is best) were used to measure the same conceptual functional outcome: Knee Injury and Osteoarthritis Outcome Score Activities of Daily Living (KOOS‐ADL); Knee Society Score (KSS); Hospital for Special Surgery ... Tourniquet use for knee replacement surgery (2020) · Cochrane	no estimate extracted	5 studies · 611 participants	Moderate
Knee replacement with tourniquet vs knee replacement without tourniquet Global assessment of success Participants reporting overall successful treatment and satisfactione Tourniquet use for knee replacement surgery (2020) · Cochrane	RR 1 [0.91, 1.1]	1 study · 100 participants	Low
Knee replacement with tourniquet vs knee replacement without tourniquet Health‐related quality of life SF‐12 mental component from zero to 100 (100 is best) Tourniquet use for knee replacement surgery (2020) · Cochrane	no estimate extracted	1 study · 199 participants	Low
Knee replacement with tourniquet vs knee replacement without tourniquet Serious adverse events Tourniquet use for knee replacement surgery (2020) · Cochrane	RR 1.73 [1.1, 2.73]	21 studies · 1799 participants	Moderate
Knee replacement with tourniquet vs knee replacement without tourniquet Cognitive function Tourniquet use for knee replacement surgery (2020) · Cochrane	no estimate extracted	NR	No studies
Knee replacement with tourniquet vs knee replacement without tourniquet Survival of the implant Risk of revision At 1 year Tourniquet use for knee replacement surgery (2020) · Cochrane	RR 1.44 [0.23, 8.92]	3 studies · 214 participants	Very low
Intervention NR Pain · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative… Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy (2020) · Cochrane	no estimate extracted	2 studies · 92 participants	Low
Intervention NR Function · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative… Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy (2020) · Cochrane	no estimate extracted	2 studies · 92 participants	Low
Intervention NR Participant‐rated global assessment of treatment success · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative… Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Quality of life · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative… Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy (2020) · Cochrane	no estimate extracted	1 study · 41 participants	Low
Intervention NR Adverse events (total): · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative… Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy (2020) · Cochrane	RR 0.5 [0.14, 1.74]	1 study · 42 participants	Very low
Intervention NR Adverse events (serious ‐ resulting in hospitalisation or death) · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative… Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy (2020) · Cochrane	no estimate extracted	1 study · 42 participants	Very low
Intervention NR Revision, re‐operation, or treatment failure · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative… Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy (2020) · Cochrane	RR 0.74 [0.22, 2.46]	3 studies · 125 participants	Very low
Intervention NR Change in pain Visual Analog Scale (VAS) at 12 weeks (0 to 10 scale; lower score means less pain) · people with rheumatoid arthritis Tai Chi for rheumatoid arthritis (2019) · Cochrane	no estimate extracted	2 studies · 81 participants	Very low
Intervention NR Change in measure of disease activity Disease Activity Score (DAS‐28‐ESR) at 12 weeks (0 to 10 score; lower score means less disease activity) · people with rheumatoid arthritis Tai Chi for rheumatoid arthritis (2019) · Cochrane	no estimate extracted	1 study · 43 participants	Very low
Intervention NR Change in function Health Assessment Questionnaire (HAQ) at 12 weeks (0 to 3 score; lower score means better function) · people with rheumatoid arthritis Tai Chi for rheumatoid arthritis (2019) · Cochrane	no estimate extracted	2 studies · 63 participants	Very low